{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:39:32Z","timestamp":1779201572754,"version":"3.51.4"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T00:00:00Z","timestamp":1598659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s11914-020-00604-4","type":"journal-article","created":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T05:03:01Z","timestamp":1598677381000},"page":"449-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Bone-Targeting Systems to Systemically Deliver Therapeutics to Bone Fractures for Accelerated Healing"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2329-1299","authenticated-orcid":false,"given":"Jeffery J.","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart A.","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,29]]},"reference":[{"key":"604_CR1","unstructured":"The Bone and Joint Initative. The burden of musculoskeletal diseases in the United States. 4th; 2019."},{"issue":"1","key":"604_CR2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s12018-012-9124-z","volume":"11","author":"JS Nyman","year":"2013","unstructured":"Nyman JS. Effect of diabetes on the fracture resistance of bone. Clin Rev Bone Miner Metab. 2013;11(1):38\u201348.","journal-title":"Clin Rev Bone Miner Metab"},{"issue":"4","key":"604_CR3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.bone.2010.12.016","volume":"48","author":"JS Nyman","year":"2011","unstructured":"Nyman JS, Even JL, Jo CH, Herbert EG, Murry MR, Cockrell GE, et al. Increasing duration of type 1 diabetes perturbs the strength-structure relationship and increases brittleness of bone. Bone. 2011;48(4):733\u201340.","journal-title":"Bone."},{"key":"604_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bonr.2017.07.001","volume":"7","author":"JS Nyman","year":"2017","unstructured":"Nyman JS, Kalaitzoglou E, Clay Bunn R, Uppuganti S, Thrailkill KM, Fowlkes JL. Preserving and restoring bone with continuous insulin infusion therapy in a mouse model of type 1 diabetes. Bone Rep. 2017;7:1\u20138.","journal-title":"Bone Rep"},{"issue":"15","key":"604_CR5","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2106\/JBJS.18.01297","volume":"101","author":"S Henderson","year":"2019","unstructured":"Henderson S, Ibe I, Cahill S, Chung YH, Lee FY. Bone quality and fracture-healing in type-1 and type-2 diabetes mellitus. J Bone Jt Surg Am Vol. 2019;101(15):1399\u2013410.","journal-title":"J Bone Jt Surg Am Vol"},{"issue":"1","key":"604_CR6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/2151458510378105","volume":"1","author":"S Schnell","year":"2010","unstructured":"Schnell S, Friedman SM, Mendelson DA, Bingham KW, Kates SL. The 1-year mortality of patients treated in a hip fracture program for elders. Geriatr Orthop Surg Rehabil. 2010;1(1):6\u201314.","journal-title":"Geriatr Orthop Surg Rehabil"},{"issue":"4","key":"604_CR7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5312\/wjo.v5.i4.402","volume":"5","author":"P Carpintero","year":"2014","unstructured":"Carpintero P, Caeiro JR, Carpintero R, Morales A, Silva S, Mesa M, et al. Complications of hip fractures : a review. World J Orthop. 2014;5(4):402\u201311.","journal-title":"World J Orthop"},{"issue":"1","key":"604_CR8","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrrheum.2014.164","volume":"11","author":"TA Einhorn","year":"2015","unstructured":"Einhorn TA, Gerstenfeld L. Fracture healing: mechanisms and interventions. Nat Rev Rheumatol. 2015;11(1):45\u201354.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"604_CR9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00264-007-0422-x","volume":"31","author":"AP White","year":"2007","unstructured":"White AP, Vaccaro AR, Hall JA, Whang PG, Friel BC, McKee MD. Clinical applications of BMP-7\/OP-1 in fractures, nonunions and spinal fusion. Int Orthop. 2007;31(6):735\u201341.","journal-title":"Int Orthop"},{"issue":"16 SUPPL","key":"604_CR10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/00007632-200208151-00004","volume":"27","author":"S Ebara","year":"2002","unstructured":"Ebara S, Nakayama K. Mechanism for the action of bone morphogenetic proteins and regulation of their activity. Spine (Phila Pa 1976). 2002;27(16 SUPPL):10\u20135.","journal-title":"Spine (Phila Pa 1976)"},{"issue":"3\u20134","key":"604_CR11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1089\/ten.tea.2011.0008","volume":"18","author":"E Bergeron","year":"2012","unstructured":"Bergeron E, Leblanc E, Drevelle O, Gigu\u00e8re R, Beauvais S, Grenier G, et al. The evaluation of ectopic bone formation induced by delivery systems for bone morphogenetic protein-9 or its derived peptide. Tissue Eng A. 2012;18(3\u20134):342\u201352.","journal-title":"Tissue Eng A"},{"issue":"8","key":"604_CR12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1210\/js.2018-00118","volume":"2","author":"AV Haas","year":"2018","unstructured":"Haas AV, LeBoff MS. Osteoanabolic agents for osteoporosis. J Endocr Soc. 2018;2(8):922\u201332.","journal-title":"J Endocr Soc"},{"key":"604_CR13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.actbio.2014.09.006","volume":"11","author":"L Kyll\u00f6nen","year":"2015","unstructured":"Kyll\u00f6nen L, D\u2019Este M, Alini M, Eglin D. Local drug delivery for enhancing fracture healing in osteoporotic bone. Acta Biomater. 2015;11:412\u201334.","journal-title":"Acta Biomater"},{"key":"604_CR14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.biomaterials.2017.06.001","volume":"139","author":"Y Wang","year":"2017","unstructured":"Wang Y, Malcolm DW, Benoit DSW. Controlled and sustained delivery of siRNA\/NPs from hydrogels expedites bone fracture healing. Biomaterials. 2017;139:127\u201338.","journal-title":"Biomaterials."},{"issue":"6","key":"604_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5005\/jcdp-8-6-25","volume":"8","author":"ML Bhongade","year":"2007","unstructured":"Bhongade ML, Tiwari IR. A comparative evaluation of the effectiveness of an anorganic bone matrix\/cell binding peptide with an open flap debridement in human infrabony defects: a clinical and radiographic study. J Contemp Dent Pract. 2007;8(6):25\u201334.","journal-title":"J Contemp Dent Pract"},{"key":"604_CR16","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1073\/pnas.1321717111","volume":"111","author":"YRV Shih","year":"2014","unstructured":"Shih YRV, Hwang Y, Phadke A, Kang H, Hwang NS, Caro EJ, et al. Calcium phosphate-bearing matrices induce osteogenic differentiation of stem cells through adenosine signaling. Proc Natl Acad Sci U S A. 2014;111:990\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"C","key":"604_CR17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1525-1497.2005.00219.x","volume":"20","author":"LA Beaupre","year":"2005","unstructured":"Beaupre LA, Jones CA, Saunders LD, Johnston DWC, Frcs C, Buckingham J, et al. Best practices for elderly hip fracture patients a systematic overview of the evidence. J Gen Intern Med [Internet]. 2005;20(C):1019\u201325 Available from: http:\/\/www.labolsa.com\/finanzas\/precio+del+aluminio+por+kilo+en+colombia.","journal-title":"J Gen Intern Med [Internet]"},{"issue":"1","key":"604_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.afos.2018.03.002","volume":"4","author":"MR McClung","year":"2018","unstructured":"McClung MR. Romosozumab for the treatment of osteoporosis. Osteoporos Sarcopenia [internet]. 2018;4(1):11\u20135. https:\/\/doi.org\/10.1016\/j.afos.2018.03.002.","journal-title":"Osteoporos Sarcopenia [internet]"},{"issue":"1","key":"604_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/17453674.2015.1073050","volume":"87","author":"T Johansson","year":"2016","unstructured":"Johansson T. PTH 1-34 ( teriparatide ) may not improve healing in proximal humerus fractures. Acta Orthop. 2016;87(1):79\u201382.","journal-title":"Acta Orthop"},{"issue":"5","key":"604_CR20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s11999-015-4669-z","volume":"474","author":"M Bhandari","year":"2016","unstructured":"Bhandari M, Jin L, See K, Burge R, Mbchb NG, Witvrouw R, et al. Does teriparatide improve femoral neck fracture healing : results from a randomized placebo-controlled trial. Clin Orthop Relat Res. 2016;474(5):1234\u201344.","journal-title":"Clin Orthop Relat Res"},{"issue":"2","key":"604_CR21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1359\/jbmr.090731","volume":"25","author":"HA Prospective","year":"2010","unstructured":"Prospective HA, Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures*. JBMR. 2010;25(2):404\u201314.","journal-title":"JBMR."},{"issue":"2","key":"604_CR22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3109\/17453671003761946","volume":"81","author":"P Aspenberg","year":"2010","unstructured":"Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures: analysis of a subgroup of patients within a randomized trial. Acta Orthop ISSN. 2010;81(2):234\u20136.","journal-title":"Acta Orthop ISSN"},{"issue":"4","key":"604_CR23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/ten.teb.2015.0357","volume":"22","author":"AW James","year":"2016","unstructured":"James AW, LaChaud G, Shen J, Asatrian G, Nguyen V, Zhang X, et al. A review of the clinical side effects of bone morphogenetic protein-2. Tissue Eng B Rev. 2016;22(4):284\u201397.","journal-title":"Tissue Eng B Rev"},{"issue":"7","key":"604_CR24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.addr.2004.12.017","volume":"57","author":"JE Shea","year":"2005","unstructured":"Shea JE, Miller SC. Skeletal function and structure: implications for tissue-targeted therapeutics. Adv Drug Deliv Rev. 2005;57(7):945\u201357.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"604_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.otsr.2011.10.011","volume":"98","author":"X Roussignol","year":"2012","unstructured":"Roussignol X, Currey C, Duparc F, Dujardin F. Indications and results for the Exogen\u2122 ultrasound system in the management of non-union: a 59-case pilot study. Orthop Traumatol Surg Res [Internet]. 2012;98(2):206\u201313. https:\/\/doi.org\/10.1016\/j.otsr.2011.10.011.","journal-title":"Orthop Traumatol Surg Res [Internet]"},{"key":"604_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jconrel.2017.11.009","volume":"269","author":"SG Rotman","year":"2018","unstructured":"Rotman SG, Grijpma DW, Richards RG, Moriarty TF, Eglin D, Guillaume O. Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics [Internet]. J Control Release. Elsevier. 2018;269:88\u201399. https:\/\/doi.org\/10.1016\/j.jconrel.2017.11.009.","journal-title":"J Control Release"},{"issue":"3","key":"604_CR27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.2018-0707","volume":"24","author":"SP Zinnen","year":"2019","unstructured":"Zinnen SP, Karpeisky A, Von Hoff DD, Plekhova L, Alexandrov A. First-in-human phase I study of MBC-11, a novel bone-targeted cytarabine-etidronate conjugate in patients with cancer-induced bone disease. Oncologist. 2019;24(3):303\u2013e102.","journal-title":"Oncologist."},{"issue":"3","key":"604_CR28","first-page":"1","volume":"10","author":"H Wang","year":"2018","unstructured":"Wang H, Xiao L, Tao J, Srinivasan V, Boyce BF, Ebetino FH, et al. Synthesis of a bone-targeted bortezomib with in vivo anti-myeloma effects in mice. Pharmaceutics. 2018;10(3):1\u201313.","journal-title":"Pharmaceutics."},{"key":"604_CR29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2015.10.005","volume":"99","author":"LE Cole","year":"2016","unstructured":"Cole LE, Vargo-Gogola T, Roeder RK. Targeted delivery to bone and mineral deposits using bisphosphonate ligands. Adv Drug Deliv Rev. 2016;99:12\u201327.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"604_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-016-0161-3","volume":"6","author":"R Bergmann","year":"2016","unstructured":"Bergmann R, Meckel M, Kub\u00ed\u010dek V, Pietzsch J, Steinbach J, Hermann P, et al. 177Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment. EJNMMI Res. 2016;6(1):1\u201312.","journal-title":"EJNMMI Res"},{"issue":"2","key":"604_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.nucmedbio.2008.11.007","volume":"36","author":"K Ogawa","year":"2009","unstructured":"Ogawa K, Kawashima H, Shiba K, Washiyama K, Yoshimoto M, Kiyono Y, et al. Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. Nucl Med Biol [Internet]. 2009;36(2):129\u201335. https:\/\/doi.org\/10.1016\/j.nucmedbio.2008.11.007.","journal-title":"Nucl Med Biol [Internet]"},{"issue":"16","key":"604_CR32","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/anie.200805133","volume":"48","author":"K Miller","year":"2009","unstructured":"Miller K, Erez R, Segal E, Shabat D, Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed. 2009;48(16):2949\u201354.","journal-title":"Angew Chem Int Ed"},{"issue":"3","key":"604_CR33","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/jbm.a.34002","volume":"100 A","author":"G Wang","year":"2012","unstructured":"Wang G, Mostafa NZ, Incani V, Kucharski C, Uluda\u011d H. Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases. J Biomed Mater Res A. 2012;100 A(3):684\u201393.","journal-title":"J Biomed Mater Res A"},{"issue":"19","key":"604_CR34","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1002\/adfm.201102357","volume":"22","author":"KR Chaudhari","year":"2012","unstructured":"Chaudhari KR, Kumar A, Khandelwal VKM, Mishra AK, Monkkonen J, Murthy RSR. Targeting efficiency and biodistribution of zoledronate conjugated docetaxel loaded pegylated pbca nanoparticles for bone metastasis. Adv Funct Mater. 2012;22(19):4101\u201314.","journal-title":"Adv Funct Mater"},{"issue":"15","key":"604_CR35","doi-asserted-by":"publisher","first-page":"3795","DOI":"10.1016\/j.biomaterials.2013.01.052","volume":"34","author":"K Miller","year":"2013","unstructured":"Miller K, Clementi C, Polyak D, Eldar-Boock A, Benayoun L, Barshack I, et al. Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. Biomaterials [Internet]. 2013;34(15):3795\u2013806. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.01.052.","journal-title":"Biomaterials [Internet]"},{"issue":"4","key":"604_CR36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3109\/1061186X.2013.877467","volume":"22","author":"L Yu","year":"2014","unstructured":"Yu L, Cai L, Hu H, Zhang Y. Experiments and synthesis of bone-targeting epirubicin with the water-soluble macromolecular drug delivery systems of oxidized-dextran. J Drug Target. 2014;22(4):343\u201351.","journal-title":"J Drug Target"},{"issue":"4","key":"604_CR37","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.bmcl.2010.01.006","volume":"20","author":"KSE Tanaka","year":"2010","unstructured":"Tanaka KSE, Dietrich E, Ciblat S, M\u00e9tayer C, Arhin FF, Sarmiento I, et al. Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis. Bioorganic Med Chem Lett. 2010;20(4):1355\u20139.","journal-title":"Bioorganic Med Chem Lett"},{"issue":"21","key":"604_CR38","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1021\/jm801007z","volume":"51","author":"TJ Houghton","year":"2008","unstructured":"Houghton TJ, Tanaka KSE, Kang T, Dietrich E, Lafontaine Y, Delorme D, et al. Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis. J Med Chem. 2008;51(21):6955\u201369.","journal-title":"J Med Chem"},{"key":"604_CR39","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1021\/acs.jmedchem.6b01615","volume":"60","author":"PP Sedghizadeh","year":"2017","unstructured":"Sedghizadeh PP, Sun S, Junka AF, Richard E, Sadrerafi K, Mahabady S, et al. Design, synthesis, and antimicrobial evaluation of a novel bone-targeting bisphosphonate-ciprofloxacin conjugate for the treatment of osteomyelitis biofilms. J Med Chem. 2017;60:2326\u201343.","journal-title":"J Med Chem"},{"issue":"11","key":"604_CR40","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/j.biomaterials.2007.12.023","volume":"29","author":"XM Liu","year":"2008","unstructured":"Liu XM, Wiswall AT, Rutledge JE, Akhter MP, Cullen DM, Reinhardt RA, et al. Osteotropic \u03b2-cyclodextrin for local bone regeneration. Biomaterials. 2008;29(11):1686\u201392.","journal-title":"Biomaterials."},{"issue":"6","key":"604_CR41","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.bmc.2012.01.024","volume":"20","author":"S Arns","year":"2012","unstructured":"Arns S, Gibe R, Moreau A, Monzur Morshed M, Young RN. Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis. Bioorganic Med Chem. 2012;20(6):2131\u201340.","journal-title":"Bioorganic Med Chem"},{"issue":"6","key":"604_CR42","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1021\/acs.bioconjchem.5b00160","volume":"26","author":"G Chen","year":"2015","unstructured":"Chen G, Arns S, Young RN. Determination of the rat in vivo pharmacokinetic profile of a bone-targeting dual-action pro-drug for treatment of osteoporosis. Bioconjug Chem. 2015;26(6):1095\u2013103.","journal-title":"Bioconjug Chem"},{"issue":"5","key":"604_CR43","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0968-0896(99)00045-0","volume":"7","author":"L Gil","year":"1999","unstructured":"Gil L, Han Y, Opas EE, Rodan GA, Ruel R, Seedor JG, et al. Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg Med Chem. 1999;7(5):901\u201319.","journal-title":"Bioorg Med Chem"},{"issue":"4","key":"604_CR44","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jbmr.2382","volume":"30","author":"CC Liu","year":"2015","unstructured":"Liu CC, Hu S, Chen G, Georgiou J, Arns S, Kumar NS, et al. Novel EP4 receptor agonist-bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the ovariectomized rat model of postmenopausal bone loss. J Bone Miner Res. 2015;30(4):670\u201380.","journal-title":"J Bone Miner Res"},{"key":"604_CR45","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bmc.2009.12.041","volume":"18","author":"M Morioka","year":"2010","unstructured":"Morioka M, Kamizono A, Takikawa H, Mori A, Ueno H, Kadowaki S-i, et al. Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. Bioorg Med Chem. 2010;18:1143\u20138.","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"604_CR46","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1016\/j.biomaterials.2013.01.059","volume":"34","author":"JN Yewle","year":"2013","unstructured":"Yewle JN, Puleo DA, Bachas LG. Bifunctional bisphosphonates for delivering PTH (1-34) to bone mineral with enhanced bioactivity. Biomaterials [Internet]. 2013;34(12):3141\u20139. https:\/\/doi.org\/10.1016\/j.biomaterials.2013.01.059.","journal-title":"Biomaterials [Internet]"},{"issue":"4","key":"604_CR47","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s13346-017-0407-2","volume":"7","author":"Y Yang","year":"2017","unstructured":"Yang Y, Aghazadeh-Habashi A, Panahifar A, Wu Y, Bhandari KH, Doschak MR. Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats. Drug Deliv Transl Res. 2017;7(4):482\u201396.","journal-title":"Drug Deliv Transl Res"},{"issue":"11","key":"604_CR48","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.00387-09","volume":"53","author":"F Chen","year":"2009","unstructured":"Chen F, Liu XM, Rice KC, Li X, Yu F, Reinhardt RA, et al. Tooth-binding micelles for dental caries prevention. Antimicrob Agents Chemother. 2009;53(11):4898\u2013902.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"604_CR49","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1902\/jop.2012.110683","volume":"83","author":"AC Killeen","year":"2012","unstructured":"Killeen AC, Rakes PA, Schmid MJ, Zhang Y, Narayana N, Marx DB, et al. Impact of local and systemic alendronate on simvastatin-induced new bone around periodontal defects. J Periodontol. 2012;83(12):1463\u201371.","journal-title":"J Periodontol"},{"key":"604_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bone.2014.07.026","volume":"70","author":"W Yao","year":"2015","unstructured":"Yao W, Lane NE. Targeted delivery of mesenchymal stem cells to the bone. Bone [Internet]. 2015;70:62\u20135. https:\/\/doi.org\/10.1016\/j.bone.2014.07.026.","journal-title":"Bone [Internet]"},{"issue":"8","key":"604_CR51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0135966","volume":"10","author":"H Katsumi","year":"2015","unstructured":"Katsumi H, Sano JI, Nishikawa M, Hanzawa K, Sakane T, Yamamoto A. Molecular design of bisphosphonate-modified proteins for efficient bone targeting in vivo. PLoS One. 2015;10(8):1\u201315.","journal-title":"PLoS One"},{"key":"604_CR52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.addr.2015.10.005","volume":"99","author":"LE Cole","year":"2016","unstructured":"Cole LE, Vargo-gogola T, Roeder RK. Targeted delivery to bone and mineral deposits using bisphosphonate ligands [Internet]. Adv Drug Del Rev. Elsevier B.V. 2016;99:12\u201327. https:\/\/doi.org\/10.1016\/j.addr.2015.10.005.","journal-title":"Adv Drug Del Rev"},{"issue":"4","key":"604_CR53","first-page":"324","volume":"60","author":"JP Brown","year":"2014","unstructured":"Brown JP, Morin S, Leslie MW, Papaioannou A, Cheung AM, Davison KS, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician. 2014;60(4):324\u201333.","journal-title":"Can Fam Physician"},{"issue":"November 2017","key":"604_CR54","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jconrel.2017.11.009","volume":"269","author":"SG Rotman","year":"2018","unstructured":"Rotman SG, Grijpma DW, Richards RG, Moriarty TF, Eglin D, Guillaume O. Drug delivery systems functionalized with bone mineral seeking agents for bone targeted therapeutics. J Control Release. 2018;269(November 2017):88\u201399.","journal-title":"J Control Release"},{"issue":"12","key":"604_CR55","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.addr.2012.01.012","volume":"64","author":"SA Low","year":"2012","unstructured":"Low SA, Kope\u010dek J. Targeting polymer therapeutics to bone. Adv Drug Deliv Rev [Internet]. 2012;64(12):1189\u2013204.","journal-title":"Adv Drug Deliv Rev [Internet]"},{"key":"604_CR56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.copbio.2016.02.029","volume":"40","author":"MR Newman","year":"2016","unstructured":"Newman MR, Benoit DSW. Local and targeted drug delivery for bone regeneration. Curr Opin Biotechnol. 2016;40:125\u201332.","journal-title":"Curr Opin Biotechnol"},{"issue":"1345","key":"604_CR57","first-page":"1","volume":"18","author":"M Stapleton","year":"2017","unstructured":"Stapleton M, Sawamoto K, Alm CJ, Mackenzie WG, Mason RW, Orii T, et al. Development of bone targeting drugs. Int J Mol Sci. 2017;18(1345):1\u201315.","journal-title":"Int J Mol Sci"},{"issue":"June","key":"604_CR58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","volume":"9","author":"KB Farrell","year":"2018","unstructured":"Farrell KB, Karpeisky A, Thamm DH, Zinnen S. Bisphosphonate conjugation for bone specific drug targeting. Bone Rep [internet]. 2018;9(June):47\u201360. https:\/\/doi.org\/10.1016\/j.bonr.2018.06.007.","journal-title":"Bone Rep [internet]"},{"key":"604_CR59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.coph.2018.03.010","volume":"40","author":"RN Young","year":"2018","unstructured":"Young RN, Grynpas MD. Targeting therapeutics to bone by conjugation with bisphosphonates. Curr Opin Pharmacol [internet]. 2018;40:87\u201394. https:\/\/doi.org\/10.1016\/j.coph.2018.03.010.","journal-title":"Curr Opin Pharmacol [internet]"},{"key":"604_CR60","unstructured":"Cutbirth ST. A restorative challenge: tetracycline-stained teeth. Denistry Today. 2015;(July):3\u20136."},{"key":"604_CR61","first-page":"5671","volume":"10","author":"G Chai","year":"2015","unstructured":"Chai G, Hu F. Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system. Int J Nanomedicine. 2015;10:5671\u201385.","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"604_CR62","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.bmcl.2008.12.051","volume":"19","author":"JR Neale","year":"2009","unstructured":"Neale JR, Richter NB, Merten KE, Taylor KG, Singh S, Waite LC, et al. Bioorganic & Medicinal Chemistry Letters Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg Med Chem Lett [Internet]. 2009;19(3):680\u20133. https:\/\/doi.org\/10.1016\/j.bmcl.2008.12.051.","journal-title":"Bioorg Med Chem Lett [Internet]"},{"key":"604_CR63","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1021\/acs.biomac.5b00777","volume":"16","author":"SA Low","year":"2015","unstructured":"Low SA, Galliford CV, Yang J, Low PS, City SL, Chemistry P, et al. Biodistribution of fracture-targeted GSK3\u03b2 inhibitor-loaded micelles for improved fracture healing. Biomacromolecules. 2015;16:3145\u201353.","journal-title":"Biomacromolecules"},{"issue":"3","key":"604_CR64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/nnm-2016-0340","volume":"12","author":"SA Low","year":"2017","unstructured":"Low SA, Galliford CV, Jones-Hall YL, Roy J, Yang J, Low PS, et al. Healing efficacy of fracture-targeted GSK3\u03b2 inhibitor-loaded micelles for improved fracture repair. Nanomedicine [internet]. 2017;12(3):185\u201393.","journal-title":"Nanomedicine [internet]"},{"key":"604_CR65","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1021\/acs.bioconjchem.8b00660","volume":"29","author":"M Wang","year":"2018","unstructured":"Wang M, Park S, Nam Y, Nielsen J, Low SA, Srinivasarao M, et al. Bone-fracture-targeted dasatinib-oligoaspartic acid conjugate potently accelerates fracture repair [Internet]. Bioconjugate Chem. 2018;29:3800\u20139.","journal-title":"Bioconjugate Chem"},{"key":"604_CR66","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1021\/ma971629y","volume":"31","author":"T Nakato","year":"1998","unstructured":"Nakato T, Yoshitake M, Matsubara K, Tomida M, Kakuchi T. Relationships between structure and properties of poly(aspartic acid)s. Macromolecules. 1998;31:2107\u201313.","journal-title":"Macromolecules"},{"key":"604_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-008-0004-z","volume":"27","author":"J Ishizaki","year":"2009","unstructured":"Ishizaki J, Waki Y, Takahashi-Nishioka T, Yokogawa K, Miyamoto KI. Selective drug delivery to bone using acidic oligopeptides. J Bone Miner Metab. 2009;27:1\u20138.","journal-title":"J Bone Miner Metab"},{"key":"604_CR68","doi-asserted-by":"crossref","unstructured":"Sekido T, Sakura N, Higashi Y, Miya K, Nitta Y, Nomura M, et al. Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. Vol. 9, Journal of Drug Targeting. 2001. 111\u2013121 p.","DOI":"10.3109\/10611860108997922"},{"issue":"1","key":"604_CR69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"K Ogawa","year":"2017","unstructured":"Ogawa K, Ishizaki A, Takai K, Kitamura Y, Makino A, Kozaka T, et al. Evaluation of Ga-DOTA-(D-Asp)n as bone imaging agents: D-aspartic acid peptides as carriers to bone. Sci Rep. 2017;7(1):1\u201311.","journal-title":"Sci Rep"},{"key":"604_CR70","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.biomaterials.2017.10.053","volume":"154","author":"S Yamashita","year":"2018","unstructured":"Yamashita S, Katsumi H, Hibino N, Isobe Y, Yagi Y, Tanaka Y, et al. Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis [Internet]. Biomaterials. Elsevier Ltd. 2018;154:74\u201385. https:\/\/doi.org\/10.1016\/j.biomaterials.2017.10.053.","journal-title":"Biomaterials"},{"issue":"9","key":"604_CR71","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1021\/acsnano.7b05103","volume":"11","author":"Y Wang","year":"2017","unstructured":"Wang Y, Newman MR, Ackun-farmmer M, Baranello MP, Sheu T, Puzas JE, et al. Fracture-targeted delivery of \u03b2-catenin agonists via peptide-functionalized nanoparticles augments fracture healing. ACS Nano. 2017;11(9):9445\u201358.","journal-title":"ACS Nano"},{"issue":"7","key":"604_CR72","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.nano.2018.07.011","volume":"14","author":"Y Liu","year":"2018","unstructured":"Liu Y, Jia Z, Akhter MP, Gao X, Wang X, Wang X, et al. Bone-targeting liposome formulation of Salvianic acid A accelerates the healing of delayed fracture Union in Mice. Nanomed Nanotechnol Biol Med. 2018;14(7):2271\u201382.","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"1","key":"604_CR73","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00223-009-9312-0","volume":"86","author":"DK Yarbrough","year":"2010","unstructured":"Yarbrough DK, Hagerman E, Eckert R, He J, Choi H, Cao N, et al. Specific binding and mineralization of calcified surfaces by small peptides. Calcif Tissue Int. 2010;86(1):58\u201366.","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"604_CR74","doi-asserted-by":"crossref","first-page":"6903","DOI":"10.1074\/jbc.M114.621219","volume":"290","author":"Z Saidak","year":"2015","unstructured":"Saidak Z, Le Henaff C, Azzi S, Marty C, Da Nascimento S, Sonnet P, et al. Wnt\/beta-catenin signaling mediates osteoblast differentiation triggered by peptide-induced alpha 5 beta1 integrin priming in mesenchymal skeletal cells. J Biol Chem. 2015;290(11):6903\u201312.","journal-title":"J Biol Chem"},{"issue":"7","key":"604_CR75","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.biomaterials.2008.11.008","volume":"30","author":"SJ Segvich","year":"2009","unstructured":"Segvich SJ, Smith HC, Kohn DH. The adsorption of preferential binding peptides to apatite-based materials. Biomaterials [Internet]. 2009;30(7):1287\u201398. https:\/\/doi.org\/10.1016\/j.biomaterials.2008.11.008.","journal-title":"Biomaterials [Internet]"},{"issue":"36","key":"604_CR76","doi-asserted-by":"publisher","first-page":"9422","DOI":"10.1016\/j.biomaterials.2010.08.064","volume":"31","author":"WN Addison","year":"2010","unstructured":"Addison WN, Miller SJ, Ramaswamy J, Mansouri A, Kohn DH, McKee MD. Phosphorylation-dependent mineral-type specificity for apatite-binding peptide sequences. Biomaterials [Internet]. 2010;31(36):9422\u201330. https:\/\/doi.org\/10.1016\/j.biomaterials.2010.08.064.","journal-title":"Biomaterials [Internet]"},{"key":"604_CR77","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.actbio.2016.12.002","volume":"49","author":"N Dinjaski","year":"2017","unstructured":"Dinjaski N, Plowright R, Zhou S, Belton DJ, Perry CC, Kaplan DL. Osteoinductive recombinant silk fusion proteins for bone regeneration. Acta Biomater. 2017;49:127\u201339.","journal-title":"Acta Biomater"},{"key":"604_CR78","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.biomaterials.2015.09.021","volume":"73","author":"J Ramaswamy","year":"2015","unstructured":"Ramaswamy J, Nam HK, Ramaraju H, Hatch NE, Kohn DH. Inhibition of osteoblast mineralization by phosphorylated phage-derived apatite-specific peptide. Biomaterials [Internet]. 2015;73:120\u201330. https:\/\/doi.org\/10.1016\/j.biomaterials.2015.09.021.","journal-title":"Biomaterials [Internet]"},{"key":"604_CR79","doi-asserted-by":"publisher","unstructured":"Mao J, Shi X, Wu YB, Gong SQ. Identification of specific hydroxyapatite {001} binding heptapeptide by phage display and its nucleation effect. Materials. 2016;9:700. https:\/\/doi.org\/10.3390\/ma9080700.","DOI":"10.3390\/ma9080700"},{"issue":"6","key":"604_CR80","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1021\/acsnano.5b07828","volume":"10","author":"Y Sun","year":"2016","unstructured":"Sun Y, Ye X, Cai M, Liu X, Xiao J, Zhang C, et al. Osteoblast-targeting-peptide modified nanoparticle for siRNA\/microRNA delivery. ACS Nano. 2016;10(6):5759\u201368.","journal-title":"ACS Nano"},{"issue":"3","key":"604_CR81","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.3791","volume":"21","author":"C Liang","year":"2015","unstructured":"Liang C, Guo B, Wu H, Shao N, Li D, Liu J, et al. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nat Med. 2015;21(3):288\u201394.","journal-title":"Nat Med"},{"issue":"12","key":"604_CR82","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s11095-008-9706-0","volume":"25","author":"SC Miller","year":"2008","unstructured":"Miller SC, Pan H, Wang D, Bowman BM, Kope\u010dkov\u00e1 P, Kope\u010dek J. Feasibility of using a bone-targeted, macromolecular delivery system coupled with prostaglandin E1 to promote bone formation in aged, estrogen-deficient rats. Pharm Res. 2008;25(12):2889\u201395.","journal-title":"Pharm Res"},{"key":"604_CR83","doi-asserted-by":"publisher","unstructured":"Vincent K, Durrant MC. Journal of Molecular Graphics and Modelling A structural and functional model for human bone sialoprotein [Internet]. Vol. 39, Journal of Molecular Graphics and Modelling. Elsevier Inc.; 2013. 108\u2013117 p. https:\/\/doi.org\/10.1016\/j.jmgm.2012.10.007","DOI":"10.1016\/j.jmgm.2012.10.007"},{"key":"604_CR84","doi-asserted-by":"publisher","unstructured":"Tavafoghi M, Cerruti M. The role of amino acids in hydroxyapatite mineralization. J R Soc Interface. 2016;13:20160462.https:\/\/doi.org\/10.1098\/rsif.2016.0462.","DOI":"10.1098\/rsif.2016.0462"},{"key":"604_CR85","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jconrel.2017.07.018","volume":"262","author":"S Yamashita","year":"2017","unstructured":"Yamashita S, Katsumi H, Hibino N, Isobe Y, Yagi Y, Kusamori K, et al. Development of PEGylated carboxylic acid-modified polyamidoamine dendrimers as bone-targeting carriers for the treatment of bone diseases [Internet]. J Control Release. Elsevier. 2017;262:10\u20137. https:\/\/doi.org\/10.1016\/j.jconrel.2017.07.018.","journal-title":"J Control Release"},{"issue":"1","key":"604_CR86","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1006\/bbrc.2001.5553","volume":"287","author":"M Matsumoto","year":"2001","unstructured":"Matsumoto M, Hosoda H, Kitajima Y, Morozumi N, Minamitake Y, Tanaka S, et al. Structure-activity relationship of ghrelin: pharmacological study of ghrelin peptides. Biochem Biophys Res Commun. 2001;287(1):142\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"604_CR87","doi-asserted-by":"crossref","unstructured":"Wang D, Sima M, Mosley RL, Davda JP, Tietze N, Miller SC, et al. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm. 2006;3(6):717\u201325.","DOI":"10.1021\/mp0600539"},{"issue":"12","key":"604_CR88","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1007\/s11095-008-9605-4","volume":"25","author":"T Takahashi","year":"2008","unstructured":"Takahashi T, Yokogawa K, Sakura N, Nomura M, Kobayashi S, Miyamoto KI. Bone-targeting of quinolones conjugated with an acidic oligopeptide. Pharm Res. 2008;25(12):2881\u20138.","journal-title":"Pharm Res"},{"issue":"11","key":"604_CR89","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1021\/bc500392x","volume":"25","author":"SA Low","year":"2014","unstructured":"Low SA, Yang J, Kope\u010dek J. Bone-targeted acid-sensitive doxorubicin conjugate micelles as potential osteosarcoma therapeutics. Bioconjug Chem. 2014;25(11):2012\u201320.","journal-title":"Bioconjug Chem"},{"issue":"7","key":"604_CR90","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1021\/bc400197f","volume":"24","author":"M Yanagi","year":"2013","unstructured":"Yanagi M, Uehara T, Uchida Y, Kiyota S, Kinoshita M, Higaki Y, et al. Chemical design of 99mTc-labeled probes for targeting osteogenic bone region. Bioconjug Chem. 2013;24(7):1248\u201355.","journal-title":"Bioconjug Chem"},{"key":"604_CR91","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.biomaterials.2016.11.010","volume":"114","author":"Y Wang","year":"2017","unstructured":"Wang Y, Yang J, Liu H, Wang X, Zhou Z, Huang Q, et al. Osteotropic peptide-mediated bone targeting for photothermal treatment of bone tumors [Internet]. Biomaterials. Elsevier Ltd. 2017;114:97\u2013105. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.11.010.","journal-title":"Biomaterials"},{"issue":"February","key":"604_CR92","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejpb.2018.02.023","volume":"127","author":"Y Wang","year":"2018","unstructured":"Wang Y, Newman MR, Benoit DSW. Development of controlled drug delivery systems for bone fracture-targeted therapeutic delivery: a review. Eur J Pharm Biopharm. 2018;127(February):223\u201336.","journal-title":"Eur J Pharm Biopharm"},{"key":"604_CR93","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jconrel.2014.12.028","volume":"200","author":"Z Jia","year":"2015","unstructured":"Jia Z, Zhang Y, Chen YH, Dusad A, Yuan H, Ren K, et al. Simvastatin prodrug micelles target fracture and improve healing. J Control Release [Internet]. 2015;200:23\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2014.12.028.","journal-title":"J Control Release [Internet]"},{"issue":"8","key":"604_CR94","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1007\/s11095-016-1932-2","volume":"33","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Jia Z, Yuan H, Dusad A, Ren K, Wei X, et al. The evaluation of therapeutic efficacy and safety profile of simvastatin prodrug micelles in a closed fracture mouse model. Pharm Res [Internet]. 2016;33(8):1959\u201371. https:\/\/doi.org\/10.1007\/s11095-016-1932-2.","journal-title":"Pharm Res [Internet]"},{"issue":"3","key":"604_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms17030428","volume":"17","author":"L Dang","year":"2016","unstructured":"Dang L, Liu J, Li F, Wang L, Li D, Guo B, et al. Targeted delivery systems for molecular therapy in skeletal disorders. Int J Mol Sci. 2016;17(3):1\u201315.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"604_CR96","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nm.2617","volume":"18","author":"G Zhang","year":"2012","unstructured":"Zhang G, Guo B, Wu H, Tang T, Zhang BT, Zheng L, et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med. 2012;18(2):307\u201314.","journal-title":"Nat Med"},{"key":"604_CR97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"Z-b Huang","year":"2016","unstructured":"Huang Z-b, Shi X, Mao J, Gong SQ. Design of a hydroxyapatite-binding antimicrobial peptide with improved retention and antibacterial efficacy for oral pathogen control. Scie Rep. Nat Publ Group. 2016;6:1\u201311.","journal-title":"Scie Rep"},{"key":"604_CR98","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jconrel.2016.01.007","volume":"240","author":"H Wahyudi","year":"2016","unstructured":"Wahyudi H, Reynolds AA, Li Y, Owen SC, Yu SM. Targeting collagen for diagnostic imaging and therapeutic delivery. J Control Release. 2016;240:323\u201331.","journal-title":"J Control Release"},{"key":"604_CR99","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.drudis.2013.07.015","volume":"19","author":"T Ponnapakkam","year":"2014","unstructured":"Ponnapakkam T, Katikaneni R, Sakon J, Stratford R, Gensure RC. Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discovery Today. 2014;19:204\u20138.","journal-title":"Drug Discovery Today"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00604-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-020-00604-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00604-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T23:29:34Z","timestamp":1630193374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-020-00604-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,29]]},"references-count":99,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1007\/s11914-020-00604-4","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,29]]},"assertion":[{"value":"29 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Jeffery Nielsen reports having patents pending.Dr. Stewart Low reports that he is an employee of Novosteo, which works on targeting bone anabolics to fractures. This is primarily why he understands the field in such depth, qualifying him to discuss the topic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}